Rationale and Design of a Phase 3 Open-label Extension Study of Fixed Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea

aroxybutynin/atomoxetine (AD109) - Apnimed

https://www.atsjournals.org/doi/abs/10.1164/ajrccm.2025.211.Abstracts.A6934

Sanjay R. Patel, MD, MS, ATSF; Ronald Farkas, MD; Stephen D. Pittman, MS; John Cronin, MD; Ali Azarbarzin, PhD; Patrick J. Strollo, MD; Luigi Taranto-Montemurro, MD; Ketan Mehta, MS

Feb 24, 2025